Company	Price	Valuation					Profitability					Cash & leverage					Quality				Rating
		P/E	P/B	P/S	EV / EBITDA	DCF upside	Gross margin	Operating margin	Net margin	ROE	ROIC	FCF yield	Debt / equity	Net debt / EBITDA	Interest coverage	Current ratio	Dividend yield	Piotroski (0-9)	Altman Z	Rating score (1-5)
NVCTthis companyNuvectis Pharma, Inc.	$20.63	-5.72×	8.94×	0×	-5.03×	-93.9%	0.0%	0.0%	0.0%	-143.6%	-149.8%	-9.7%	0×	1.2×	0×	2.38×	0.0%	1	17.43	1	D+
CMPXCompass Therapeutics, Inc.	$0.80	-12.79×	4.3×	0×	-12.7×	-84.0%	0.0%	0.0%	0.0%	-33.8%	-35.3%	-5.8%	0.05×	0.32×	0×	15.02×	0.0%	3	-0.29	2	C+
IMMXImmix Biopharma, Inc.	$8.48	-5.88×	1.84×	0×	-2.69×	-63.4%	0.0%	0.0%	0.0%	-31.4%	-31.6%	-14.3%	0.01×	3.14×	0×	10.01×	0.0%	2	35.26	2	C+
IMRXImmuneering Corporation	$3.60	-5.18×	1.33×	0×	-2.96×	-19.7%	0.0%	0.0%	0.0%	-25.6%	-26.7%	-15.7%	0.02×	2.24×	0×	17.5×	0.0%	0	6.81	2	B-
JANXJanux Therapeutics, Inc.	$13.70	-7.54×	0.89×	85.51×	-7.39×	-118.0%	79.7%	-1576.7%	-1136.3%	-11.9%	-16.0%	-9.7%	0.02×	0.27×	0×	39.04×	0.0%	3	8.27	2	C+
MGNXMacroGenics, Inc.	$2.47	-1.36×	1.83×	0.68×	-2.54×	-2714.5%	71.1%	-48.7%	-49.9%	-134.2%	-33.0%	-81.6%	1.92×	-0.83×	-8.56×	5.1×	0.0%	1	-4.43	1	D+
Peer median	—	-5.88×	1.83×	0×	-2.96×	-84.0%	0.0%	0.0%	0.0%	-31.4%	-31.6%	-14.3%	0.02×	0.32×	0×	15.02×	0.0%	2	6.81	2	—